Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss.

This study aimed to compare the efficacy and safety of ossein-hydroxyapatite complex (OHC) versus calcium carbonate (CC) for preventing bone loss during perimenopause in current clinical practice. The prospective, comparative, non-randomized, open-label study included 851 perimenopausal women with basal bone mineral density (BMD) -score ≥-2 standard deviations (SDs). Participants received either OHC (712 mg calcium/day) or CC (1000 mg calcium/day) over 3 years.

Prevention of osteoporosis: four-year follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound.

Background: The long-term effects of ossein-hydroxyapatite compound (OHC), a drug used for osteoporosis prevention, have not been previously reported. The aim of this study was to assess the long-term efficacy of OHC in postmenopausal women with bone mineral density (BMD) in the osteopenia range.

Methods: We performed a retrospective 4-year follow-up study in a primary-care setting to assess changes in BMD in a cohort of 112 postmenopausal women included in an osteoporosis programme that included health and dietary advice and who were treated with OHC 1660mg every 12 hours.

[Chondroma of the larynx. Apropos of a case].

Tumours originating from the laryngeal skeleton are a rarity. We present a case report of an 82 year old male with chondroma in the larynx. 23 years before, the tumour was diagnosed when the patient was asymptomatic.